As Endogena Therapeutics is moving into the next phase from a pre-clinical to a clinical stage company, we are pleased to announce that Michael Lai has joined our team as Medical Director Clinical Development on April 1st, 2022.
“We are excited to kick-off this critical stage in our company’s development with such a high-profile candidate as Michael in our team” says Matthias Steger, CEO & Co-Founder.
Michael Lai, MBBS, MBA, is a specialist pharmaceutical physician with over 20 years of clinical research experience. He has been involved in the clinical development of therapies in diverse therapeutic areas, including ophthalmology, cardiology, immunology, and infectious diseases, and has supported successful registrations in the US, EU, China, Japan and Australia.
Michael obtained his medical degree from the University of Western Australia, his MBA from the Australian Graduate School of Management and is a Fellow of the Faculty of Pharmaceutical Medicine in the UK.
Welcome to the Endogena team, Michael!